البحث في مجموعات البراءات الوطنية والدولية
بعض محتويات هذا التطبيق غير متوفرة في الوقت الحالي.
إذا استمرت هذه الحالة ، يرجى الاتصال بنا علىتعليق وإتصال
1. (WO2019032999) PHOTORECEPTOR GENE MODULATOR PHOTOREGULIN 3 FOR TREATMENT OF RETINAL DISEASE
ملاحظة: نص مبني على عمليات التَعرف الضوئي على الحروف. الرجاء إستخدام صيغ PDF لقيمتها القانونية

CLAIMS

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method for decreasing rod gene expression in a retina, comprising contacting a retina with a compound of formula (I):


or a pharmaceutically acceptable salt thereof.

2. The method of Claim 1, wherein the rod gene is selected from the group consisting of Nrl, Nr2e3, Rho, and Gnatl.

3. The method of Claim 1, wherein contacting the retina comprises systemic administration or intravitreal injection.

4. The method of Claim 1, wherein the retina is a retina of a human subject.

5. A method for treating a disease or condition treatable by decreasing rod gene expression in a retina, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):


or a pharmaceutically acceptable salt thereof.

6. The method of Claim 5, wherein the disease or condition is selected from the group consisting of retinitis pigmentosa, retinal degeneration, macular degeneration, age-related macular degeneration, Stargardt's macular dystrophy, retinal dystrophy, Sorsby's fundus dystrophy, diabetic retinopathy, diabetic maculopathy, retinopathy of prematurity, and ischemia reperfusion related retinal injury.

7. The method of Claim 5, wherein the retinal disease is retinitis pigmentosa.

8. The method of Claim 5, wherein administering the compound comprises systemic administration or intravitreal injection.

9. The method of Claim 5, wherein the subject is a human.

10. A method for decreasing rhodopsin expression in a retina, comprising treating a retina with a compound of formula (I):


or a pharmaceutically acceptable salt thereof.

11. The method of Claim 10, wherein the retina is a retina of a human subject.

12. A method of treating a retinal disease in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):


or a pharmaceutically acceptable salt thereof.

13. The method of Claim 12, wherein the retinal disease is selected from the group consisting of retinitis pigmentosa, retinal degeneration, macular degeneration, age-related macular degeneration, Stargardt's macular dystrophy, retinal dystrophy, Sorsby's fundus dystrophy, diabetic retinopathy, diabetic maculopathy, retinopathy of prematurity, and ischemia reperfusion related retinal injury.

14. The method of Claim 12, wherein the retinal disease is retinitis pigmentosa.

15. The method of Claim 12, wherein the subject is a human.

16. The method of Claim 12, wherein the administering the compound ses systemic administration or intravitreal injection.